MetaCap

BeyondSpring Inc. (BYSI)

NASDAQ: BYSIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.33-0.107 (-24.49%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BYSI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$13.66M
EPS (TTM)
-$0.20
52-week range
0.299 – 2.44
Day range
0.3164 – 0.4554
Volume / Avg
70.95K / 261.79K
Beta
—

52-week range

$0.299$2.44

BYSI stock today

On Nov 20, BYSI ended the session at $0.33, shedding $0.107 (24.49%), versus the S&P 500's 3.70% decline. Trading was light, with 70.95K shares changing hands, about 27% of the average daily volume. Shares are 86.5% below their 52-week high of $2.44, set on Dec 12, 2025 and 10.4% above the 52-week low of $0.299, near the bottom of the past year's range.

BYSI is down 79.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.8%. BeyondSpring has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BeyondSpring

Company profile

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Min Qiu
Headquarters
Florham Park, NJ
Employees
44
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, BeyondSpring generated $0 in revenue, up 0.0% from fiscal 2024. BeyondSpring reported a net loss of $1.0 million, compared with a loss of $11.1 million a year earlier.

BeyondSpring annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$0$1.35M$1.35M
Growth——-100.00%0.00%+650.56%
Net income$-1.01M$-11.12M$-21.03M$-33.28M$-64.18M
EPS (diluted)————$-1.64

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.05 vs —

BYSI news

All BYSI news

BeyondSpring peers

Health Care sector
BYSI peer companies
CompanyPrice% ChgMarket capCompare
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs BYSI
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs BYSI
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs BYSI
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs BYSI
NEUPNeuphoria Therapeutics Inc.2.35+1.29%$12.72Mvs BYSI
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs BYSI
MCRBSeres Therapeutics Inc.1.24-6.77%$12.64Mvs BYSI
CNTXContext Therapeutics Inc.0.16-5.10%$14.70Mvs BYSI

Indexes, lists and sector

BeyondSpring stock FAQ

What is BeyondSpring's stock price today?

BYSI last traded at $0.33 as of Nov 20, 4:00 PM EST, down 24.49% on the day. Prices are delayed at least 15 minutes.

Who is BeyondSpring's CEO?

Mr. Min Qiu is the chief executive officer of BeyondSpring Inc., which has about 44 employees.

What is the BYSI 52-week high?

The 52-week high for BYSI is $2.44 and the 52-week low is $0.299. The stock is currently 86.5% below its high.

Compare BYSI